Committee for Veterinary Medicinal Products (CVMP) Work Plan 2024

Therefore, the focus of the CVMP and its Working Parties will shift to the main activities related to the authorisation of veterinary medicines and the establishment of MRLs, providing guidance for industry, and on activities around antimicrobial resistance. [...] Consider the ongoing work of the EMA on Dedicated 2 Q1 2022 No the risk of nitrosamine formation or Expert group Q4 2024 presence during the manufacture of human medicines and the implications of this activity for the quality evaluation of VMPs. [...] Schwarz Key objectives • Facilitate the prudent and responsible use of antimicrobials; • Contribute to the minimisation of the risk to man and animals from AMR due to the use of antimicrobials in veterinary medicine. [...] In order to achieve the above-mentioned objective(s), EMA has instated the Joint CHMP/CVMP Working Party on the Application of the 3Rs in Regulatory Testing of Medicinal Products (J3RsWP) under the governance of the Agency's Non-clinical domain. [...] Reinforce the scientific and regulatory capacity and capability of the network The European medicines agencies network strategy to 2025 acknowledges the advances in science and technology that expand the possibilities for development of medicines and their use, increasing the demands on regulatory advice and assessment.